Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I–II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here is a complete pathological response seen in a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Willett, Christopher G, Duda, Dan G, di Tomaso, Emmanuelle, Boucher, Yves, Czito, Brian G, Vujaskovic, Zeljko, Vlahovic, Gordana, Bendell, Johanna, Cohen, Kenneth S, Hurwitz, Herbert I, Bentley, Rex, Lauwers, Gregory Y, Poleski, Martin, Wong, Terence Z, Paulson, Erik, Ludwig, Kirk A, Jain, Rakesh K
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686127/
https://ncbi.nlm.nih.gov/pubmed/17464339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncponc0813
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados